Video production and source: RAI

The interview with Professor Paolo Fiorina explores the ImmunoStem project, an advanced research program aiming to revolutionize the treatment of autoimmune diseases through the combined use of stem cells and next-generation immunomodulatory therapies. The Professor illustrates how an increasingly precise understanding of immune mechanisms is paving the way for interventions capable of preserving beta cell function, modulating the autoimmune response, and preventing disease progression.

A particular focus is dedicated to teplizumab, the first monoclonal antibody approved to delay the onset of type 1 diabetes. Fiorina explains its mechanism of action, clinical evidence, and the role it could play in a future where early diagnosis and targeted interventions will allow for a radical change in the natural history of the disease.

The interview offers a clear and accessible vision of the transformative potential of immunotherapy, highlighting how research, innovation, and international collaboration are building new therapeutic opportunities for children and young adults at risk.